NASDAQ: AZRX

SEARCH

SIGN UP

AzurRx Logo
  • About
      • Back
      • President's Message
      • Board of Directors
      • The Team
  • Science & Technology
      • Back
      • Overview
      • Programs
      • Development Pipeline
      • Cystic Fibrosis
      • Chronic Pancreatitis
      • Nosocomial Infections
      • Non-Systemic Biologics
      • Digestive Enzymes
      • Antibiotics and the Gut
  • Investors
      • Back
      • Press Releases
          • Back
          • 2019
          • 2018
          • 2017
          • 2016
          • 2015
          • 2014
      • Events
          • Back
          • Upcoming Events
          • Past Events
      • Presentation
      • Regulatory Filings
      • Financial Statements
          • Back
          • 2019
              • Back
              • Q1 2019
          • 2018
              • Back
              • Q4 2018
              • Q3 2018
              • Q2 2018
              • Q1 2018
          • 2017
              • Back
              • Q4 2017
              • Q3 2017
              • Q2 2017
              • Q1 2017
          • 2016
              • Back
              • Q4 2016
              • Q3 2016
      • Stock Info
      • Analyst Coverage
      • Corporate Governance
      • Contact Us
  • Clinical Studies
      • Back
      • Completed Clinical Studies
      • Clinical Publications
  • Collaborations
      • Back
      • Partnering with AzurRx
  • Contact
      • Back
      • Contact Us
      • Subscribe
  • Home
  • Investors
  • Press Releases
  • 2019

Menu

  • Press Releases
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
  • Events
    • Upcoming Events
    • Past Events
  • Presentation
  • Regulatory Filings
  • Financial Statements
    • 2019
      • Q1 2019
    • 2018
      • Q4 2018
      • Q3 2018
      • Q2 2018
      • Q1 2018
    • 2017
      • Q4 2017
      • Q3 2017
      • Q2 2017
      • Q1 2017
    • 2016
      • Q4 2016
      • Q3 2016
  • Stock Info
  • Analyst Coverage
  • Corporate Governance
  • Contact Us

2019 News

Filters
List of articles in category 2019 News
Title Date
AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC 14 Nov, 2019
AzurRx BioPharma CEO Issues Letter to Shareholders 22 Oct, 2019
AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data 17 Oct, 2019
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency 15 Oct, 2019
AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer 10 Oct, 2019
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients 25 Sep, 2019
AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update 13 Aug, 2019
AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock 18 Jul, 2019
AzurRx BioPharma Announces Proposed Public Offering of Common Stock 17 Jul, 2019
AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET 08 Jul, 2019
AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency 08 Jul, 2019
AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers 07 Jun, 2019
AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial 23 May, 2019
AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference 20 May, 2019
AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial 23 Apr, 2019
Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights 02 Apr, 2019
AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference 18 Mar, 2019
AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20) 15 Mar, 2019
AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting 12 Mar, 2019
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial 20 Feb, 2019
AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC 29 Nov, -0001
AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC 29 Nov, -0001
AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC 29 Nov, -0001
  • About
  • Science & Technology
  • Investors
  • Clinical Studies
  • Collaborations
  • Contact

Contact Us

AzurRx BioPharma, Inc.

760 Parkside Avenue
Downstate Biotechnology Incubator
Suite 304
Brooklyn, NY 11226 

Tel: 646-699-7855
info@azurrx.com

AzurRx SAS

Jardin des Entreprises, Bat 1
290, Chemin de Saint-Dionisy
30980 Langlade, France

Tel: +33 (0)4 66 67 08 16

SiteMap Ⓒ 2019 AzurRx All Rights Reserved. Website by Sandman Media Inc.